HELP
Cybin Inc. Common Stock
閉場中20日平均DV $3M?
Earnings 2026-06-2952W high -52.1%52W low +14.4%Fwd PER 10.6xMarket cap $215MAvg volume 660K
Company Overview
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2025 Q3 | -1.76 | $0 | -$32M |
| 2025 Q2 | -1.94 | $0 | -$49M |
| 2025 Q1 | -1.10 | $0 | -$22M |
| 2025 Q4 | -1.46 | $0 | -$22M |
| 2024 Q3 | -0.54 | $0 | -$27M |
| 2024 Q2 | -2.84 | $0 | -$26M |
| 2024 Q1 |
